SPARK Neuro Competitors and Similar CompaniesClear all

Express Diagnostics Int'l's competitors and similar companies include SurModics, SiteOne Therapeutics and Inflazome.
Express Diagnostics Int'l
Express Diagnostics Int'l
Express Diagnostics Int'l is a company that manufactures and distributes DrugCheck, onsite urine and saliva screening devices for the detection of drugs of abuse.
SurModics
SurModics
SurModics is a provider of surface modification, drug delivery and in vitro diagnostic technologies to the healthcare industry.
SiteOne Therapeutics
SiteOne Therapeutics
SiteOne Therapeutics is a company that develops therapeutics for the treatment of hypersensitivity disorders.
Inflazome
Inflazome
Inflazome engages in developing orally available drugs to address clinical unmet needs in inflammatory diseases by targeting the inflammasome.
Founding Date
Founding Date
2004
Founding Date
1979
Founding Date
2014
Founding Date
2016
Type
Type
Private
Type
Public
Type
Private
Type
Subsidiary
Tags
Locations
Locations
Blue Earth, US HQ
Locations
Eden Prairie, US HQ
Galway, IE
Eden Prairie, US
Locations
San Francisco, US HQ
Bozeman, US
Locations
Dublin 2, IE HQ
Brisbane City, AU
Cambridge, GB
Employees
Employees
17
Employees
3699% increase
Employees
2216% increase
Employees
156% decrease
Valuation ($)
Valuation ($)
N/A
Valuation ($)
539.3 m
Valuation ($)
75 m
Valuation ($)
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 17.8m
Total funding raised
$ 17m
For sources of this data, please see the company profile

View Company Profiles

SurModics
HQ
Eden Prairie, US
Employees
369↑ 9% increase

SurModics is a provider of surface modification, drug delivery and in vitro diagnostic technologies to the healthcare industry.

View company
SiteOne Therapeutics
HQ
San Francisco, US
Employees
22↑ 16% increase

SiteOne Therapeutics is a company that develops therapeutics for the treatment of hypersensitivity disorders.

View company
Inflazome
HQ
Dublin 2, IE

Inflazome engages in developing orally available drugs to address clinical unmet needs in inflammatory diseases by targeting the inflammasome.

View company